Zevra Therapeutics (ZVRA) Shares Outstanding (Diluted Average) (2015 - 2026)

Zevra Therapeutics has reported Shares Outstanding (Diluted Average) for 10 years, with the latest figure at $60.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 11.34% year-over-year to $60.2 million; the trailing twelve-month figure through Mar 2026 stood at $60.2 million (up 11.34% YoY), and the FY2025 full-year result was $57.3 million, up 23.81% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $60.2 million, up from $57.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $60.2 million in Q1 2026, with the low at $41.9 million in Q2 2024.
• Historically, Shares Outstanding (Diluted Average) has averaged $52.5 million across 3 years, with a median of $55.0 million in 2025.
• Annual changes were most pronounced in 2025 — Shares Outstanding (Diluted Average) soared 34.43% — and 2026, when it gained 11.34%.
• Zevra Therapeutics' Shares Outstanding (Diluted Average) stood at $46.3 million in 2024, then increased by 23.81% to $57.3 million in 2025, then gained by 5.18% to $60.2 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $60.2 million (Q1 2026), $57.3 million (Q4 2025), and $56.0 million (Q3 2025), per Business Quant data.